Equillium (NASDAQ:EQ) Issues Quarterly Earnings Results

Equillium (NASDAQ:EQ) released its quarterly earnings data on Thursday. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01, FiscalAI reports.

Equillium Stock Performance

Shares of NASDAQ EQ traded down $0.10 during trading hours on Thursday, hitting $1.32. The stock had a trading volume of 163,581 shares, compared to its average volume of 600,940. The firm’s 50-day moving average price is $1.63 and its two-hundred day moving average price is $2.08. Equillium has a 52 week low of $0.76 and a 52 week high of $3.54. The company has a market capitalization of $83.70 million, a P/E ratio of -6.60 and a beta of 2.08.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on EQ shares. Wall Street Zen lowered shares of Equillium from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Clear Str upgraded shares of Equillium to a “strong-buy” rating in a report on Tuesday, July 21st. Roth Capital reaffirmed a “buy” rating on shares of Equillium in a research note on Monday, October 26th. Zacks Research upgraded Equillium from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a report on Monday, September 21st. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.57.

Equillium Company Profile

Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company seeks to address immune-system dysregulation by developing treatments that selectively modulate immune-cell activity rather than broadly suppressing the immune system. Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, a protein involved in the activation and trafficking of certain T cells. The company has evaluated itolizumab in conditions including acute graft-versus-host disease and lupus nephritis.